title: ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.
abstract: Wang and colleagues demonstrate that digital droplet PCR (ddPCR) identified ESR1 mutations in 7% of primary breast cancers. ESR1 mutations were also readily detected in metastatic tissues and circulating tumor DNA in the blood. These results suggest that ddPCR may be amendable for monitoring tumor burden, and to predict relapse. See related article by Wang et al., p. 1130.
authors.affiliation: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
authors.forename: Guowei
authors.initials: G
authors.lastname: Gu
authors.affiliation: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. sfuqua@bcm.edu.
authors.forename: Suzanne A W
authors.initials: SA
authors.lastname: Fuqua
mesh_terms: D001943:Breast Neoplasms; D004273:DNA, Neoplasm / Q000097:blood; D006801:Humans; D009154:Mutation; D009364:Neoplasm Recurrence, Local
chemical_list: D004273:DNA, Neoplasm